

Targeting Human Gastrointestinal Stromal Tumor Cells with a Quadruplex-Binding Small Molecule

Mekala Gunaratnam,[†] Stephen Swank,[§] Shozeb M. Haider,[†] Katja Galesa,[†] Anthony P. Reszka,[†] Monica Beltran,[†] Francisco Cuenca,[†] Jonathan A. Fletcher,[§] and Stephen Neidle^{*,†}

CRUK Biomolecular Structure Group, School of Pharmacy, University of London, London, WC1N 1AX, U.K., and Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115

Received January 24, 2009

Most of human gastrointestinal stromal tumors (GIST) are driven by activating mutations in the proto-oncogene *KIT*, a tyrosine kinase receptor. Clinical treatment with imatinib targets the kinase domain of *KIT*, but tumor regrowth occurs as a result of the development of resistant mutations in the kinase active site. An alternative small-molecule approach to GIST therapy is described, in which the *KIT* gene is directly targeted, and thus, kinase resistance may be circumvented. A naphthalene diimide derivative has been used to demonstrate the concept of dual quadruplex targeting. This compound strongly stabilizes both telomeric quadruplex DNA and quadruplex sites in the *KIT* promoter in vitro. It is shown here that the compound is a potent inducer of growth arrest in a patient-derived GIST cell line at a concentration ($\sim 1 \mu\text{M}$) that also results in effective inhibition of telomerase activity and almost complete suppression of *KIT* mRNA and *KIT* protein expression. Molecular modeling studies with a telomeric quadruplex have been used to rationalize aspects of the experimental quadruplex melting data.

Introduction

The proto-oncogene *KIT* encodes for a 145–160 kDa tyrosine kinase receptor,¹ which regulates several key signal transduction cascades in order to control cell growth and proliferation.² As the *KIT* protein plays a critical role in establishing normal cell growth, mutations in functionally important regions, or its overexpression, result in aberrant function and can contribute to oncogenic cellular transformation in melanocyte, mast cell, myeloid, germ cell, and interstitial cell of Cajal lineages. As one example, aberrant function can result from constitutive activation of the *KIT* protein, where mutations result in constant kinase activity rather than activity only in response to the external stimulus of binding of its natural cytokine ligand, stem cell factor.²

Such gain-of-function mutations are found in several highly malignant human cancers, including gastrointestinal stromal tumors (GIST^c). More than 80% of GIST tumor cells contain activating mutations in *KIT* extracellular, cytoplasmic juxtamembrane, or kinase domains.^{3–5} These oncogenic mutations result in increased dimer formation by bringing together two *KIT* kinase molecules into proximity and facilitating autophosphorylation and consequently dysregulated cell growth. Current GIST therapy uses the drug imatinib to inhibit the phosphoactivation of the *KIT* enzyme;^{6,7} use of imatinib is directly linked to tumor regression, but the onset of resistance occurs, sometimes after several years of therapy, in most patients.^{8,9} Second-generation *KIT* kinase inhibitors have been more recently developed,¹⁰ notably the multikinase targeting compound sunitinib;^{11,12} however, the heterogeneity of patterns of mutations in the *KIT* protein and in resistance mechanisms suggests that the clinical challenges of resistance still remain to be overcome.¹³

We describe here an alternative approach to inhibiting GIST cell growth by using a small molecule (the naphthalene diimide derivative **1**, Figure 1a). We suggest that this targets two distinct categories of quadruplex DNA structures in the *KIT* gene itself: (i) induction of a quadruplex arrangement and displacement of bound telomeric proteins at the single-stranded 3' ends of telomeric DNA, resulting in inhibition of telomerase, disruption of telomere maintenance, and selective inhibition of cancer cell growth, and (ii) stabilization of guanine-rich sequences as quadruplex structures in the promoter region of the *KIT* gene, resulting in down-regulation of *KIT* expression. A wide range of small molecules have been developed to target telomeric quadruplexes.^{14,15} The targeting of promoter quadruplexes with small molecules has been less studied to date, although several reports^{16–19} have shown the feasibility of the approach in principle. The promoter region of the *KIT* gene contains sequences²⁰ with quadruplex features, and the dependence of GIST on abnormal *KIT* expression suggests that this cancer can be a paradigm for evaluating this approach. We have previously reported on a series of naphthalene diimide derivatives with potent telomeric quadruplex affinity and telomerase inhibitory activity²¹ in standard laboratory cancer cell lines. A compound from this series (Figure 1a) is examined in depth in the present study, with the aim of ascertaining if there is activity in a clinically relevant GIST cell line and, if so, whether this can be correlated with quadruplex binding and their subsequent molecular consequences.

Results

***KIT* Quadruplexes.** We have previously identified two sequences (*KIT1* and *KIT2*) in the *KIT* promoter upstream of the transcription start site that are capable of forming quadruplex structures,^{22,23} and the 3D structure of the *KIT1* quadruplex has been determined in detail.^{24,25} Both sequences are in nuclease hypersensitive regions. Since the stability of these particular quadruplexes is highly sensitive to mutations in the sequences involved, a 690 nucleotide region in the *KIT* promoter that contains these two sites, taken from the DNA of the GIST882

* To whom correspondence should be addressed. Phone: 44 207 753 5969. Fax: 44 207 753 5970. E-mail: stephen.neidle@pharmacy.ac.uk.

[†] University of London.

[§] Brigham and Women's Hospital, Harvard Medical School.

^c Abbreviations: GST, gastrointestinal stromal tumors; FRET, fluorescence resonance energy transfer.




Figure 1. Structures of (a) compound **1**, (b) BRACO-19, and (c) TMPyP4.

Table 1. Part of the 690 Nucleotide Region Immediately Upstream of the Transcription Start Site of the *KIT* Gene Sequenced in This Study, Together with Part of Exon 1 (In Mauve), Using DNA Extracted from GIST882 Cells^a

<i>KIT</i>	GCCCCCGGCATTAACACGTCGAAAGAGCAGGGGCCAGACGCCGCCGGGAAGAAGCGAGA	-107
PCR_A_1	GCCCCCGGCATTAACACGTCGAAAGAGCAGGGGCCAGACGCCGCCGGGAAGAAGCGAGA	-107
PCR_A_2	GCCCCCGGCATTAACACGTCGAAAGAGCAGGGGCCAGACGCCGCCGGGAAGAAGCGAGA	-107
PCR_A_3	GCCCCCGGCATTAACACGTCGAAAGAGCAGGGGCCAGACGCCGCCGGGAAGAAGCGAGA	-107
PCR_B_1	GCCCCCGGCATTAACACGTCGAAAGAGCAGGGGCCAGACGCCGCCGGGAAGAAGCGAGA	-107
PCR_B_2	GCCCCCGGCATTAACACGTCGAAAGAGCAGGGGCCAGACGCCGCCGGGAAGAAGCGAGA	-107
PCR_B_3	GCCCCCGGCATTAACACGTCGAAAGAGCAGGGGCCAGACGCCGCCGGGAAGAAGCGAGA	-107
<i>KIT</i>	CCCGGGCGGGCGCGAGGGAGGGGAGGCGAGGAGGGGCGTGGCCGGCGCGCAGAGGGAGGG	-48
PCR_A_1	CCCGGGCGGGCGCGAGGGAGGGGAGGCGAGGAGGGGCGTGGCCGGCGCGCAGAGGGAGGG	-48
PCR_A_2	CCCGGGCGGGCGCGAGGGAGGGGAGGCGAGGAGGGGCGTGGCCGGCGCGCAGAGGGAGGG	-48
PCR_A_3	CCCGGGCGGGCGCGAGGGAGGGGAGGCGAGGAGGGGCGTGGCCGGCGCGCAGAGGGAGGG	-48
PCR_B_1	CCCGGGCGGGCGCGAGGGAGGGGAGGCGAGGAGGGGCGTGGCCGGCGCGCAGAGGGAGGG	-48
PCR_B_2	CCCGGGCGGGCGCGAGGGAGGGGAGGCGAGGAGGGGCGTGGCCGGCGCGCAGAGGGAGGG	-48
PCR_B_3	CCCGGGCGGGCGCGAGGGAGGGGAGGCGAGGAGGGGCGTGGCCGGCGCGCAGAGGGAGGG	-48
<i>KIT</i>	CGCTGGGAGGAGGGGCTGCTGCTCGCCGCTCGCGGCTCTGGGGGCTCGGCTTTGCCGCGC	13
PCR_A_1	CGCTGGGAGGAGGGGCTGCTGCTCGCCGCTCGCGGCTCTGGGGGCTCGGCTTTGCCGCGC	13
PCR_A_2	CGCTGGGAGGAGGGGCTGCTGCTCGCCGCTCGCGGCTCTGGGGGCTCGGCTTTGCCGCGC	13
PCR_A_3	CGCTGGGAGGAGGGGCTGCTGCTCGCCGCTCGCGGCTCTGGGGGCTCGGCTTTGCCGCGC	13
PCR_B_1	CGCTGGGAGGAGGGGCTGCTGCTCGCCGCTCGCGGCTCTGGGGGCTCGGCTTTGCCGCGC	13
PCR_B_2	CGCTGGGAGGAGGGGCTGCTGCTCGCCGCTCGCGGCTCTGGGGGCTCGGCTTTGCCGCGC	13
PCR_B_3	CGCTGGGAGGAGGGGCTGCTGCTCGCCGCTCGCGGCTCTGGGGGCTCGGCTTTGCCGCGC	13

^a The sequence highlighted in cyan corresponds to the quadruplex sequence *KIT1*, and that in yellow corresponds to the quadruplex sequence *KIT2*.

cell line, was sequenced. The sequence data in Table 1 show that both sites are intact, with no mutations in or adjacent to them.

The ability of compound **1** and two other established quadruplex-binding ligands, the trisubstituted acridine experimental drug molecule BRACO-19^{26–31} and the *N*-methylpyridylporphyrin compound TMPyP4³² (Figure 1), to stabilize these quadruplexes as well as a human telomeric quadruplex and a duplex sequence, all as isolated sequences in vitro, was

evaluated by fluorescence resonance energy transfer (FRET) methods (Figure 2a). The data in Table 2 show that of the three compounds compound **1** has the greatest overall ability to stabilize the human telomeric and the *KIT2* quadruplexes, with very similar ΔT_m values for each and a significantly greater ΔT_m value for the *KIT2* quadruplex compared to either BRACO-19 or TMPyP4. It is notable that all three compounds have significantly lower ΔT_m values for the *KIT1* quadruplex compared to *KIT2*. Control experiments with imatinib show no




Figure 2. FRET melting curves. Part a shows the change in normalized fluorescent intensity with respect to temperature for the G4-Tel sequence 5'-FAM-d[G₃(T₂AG₃)₃]-TAMRA-3' at a concentration of 200 nM in potassium chloride/cacodylate buffer. The curves at four different concentrations of compound **1** show an increase in melting temperature (ΔT_m) with respect to increasing ligand concentration. Part b shows the results of competition experiments for the G4-Tel, *KIT1*, and *KIT2* quadruplexes and compound **1**, in which increasing concentrations of calf thymus DNA are added to each melting experiment. The decrease in ΔT_m for each quadruplex is a qualitative indication of relative selectivity at that quadruplex/duplex DNA ratio.

Table 2. Thermal Stabilization of Various DNAs, Expressed as ΔT_m Values in °C, for Ligand Concentrations of 0.5 μ M, Using a FRET Method^{21,a}

	G4-tel	duplex DNA	G4- <i>KIT1</i>	G4- <i>KIT2</i>
Imatinib	0.2	0.1	0.2	0.2
Compound 1	28.7	5.7	11.2	29.0
BRACO-19	21.6	7.2	6.5	18.5
TMPyP4	27.8	8.7	11.1	21.6

^a Sequences are given in the Experimental Section. The average esd is ± 0.2 °C.

significant interactions with any of these DNAs. Selectivity for quadruplex vs duplex DNA was evaluated with a competition assay, using varying ratios of calf thymus DNA (Figure 2b). This suggests a similar pattern of selectivity for all three compounds. For all three, the ΔT_m values for the telomeric quadruplex are not significantly affected by the presence of calf thymus DNA at a low duplex/quadruplex ratio but are diminished at higher ratios. The pattern of melting behavior with the *KIT2* quadruplex shows some differences at the lowest duplex/quadruplex ratio, with the ΔT_m value for compound **1** unaffected

compared to BRACO-19 and TMPyP4. The appearance of a second transition in the melting curve (Figure 2a) at low ligand concentrations is suggestive of possible folding reorganization induced by ligand binding, although slow exchange cannot be ruled out in the absence of further studies.

Molecular Modeling Studies. Several distinct native telomeric quadruplex structures are now available,³³ whose diversity demonstrates the polymorphism produced by closely related human quadruplex sequences. We have not used any of these structures as starting points for the modeling, since relevant crystal structures of quadruplex–ligand complexes are now available. The quadruplex binding of ligands **1** and BRACO-19 has been modeled by docking them into an end G-quartet face of the cocrystal structures of BRACO-19 and a naphthalene diimide compound in complexes with human telomeric quadruplexes.^{34,35} The low-energy docked positions for the planar chromophore of compound **1** are in the center of a terminal G-quartet, with the charged side chains extending into the four grooves of the quadruplex (Figure 3a). The final docked




Figure 3. Results of the docking and simulated annealing/molecular dynamics calculations, showing in each case the low-energy position of the ligand (shown in stick representation) stacked onto a terminal G-quartet, shown in solvent-accessible surface representation mode.⁴⁷ Parts a and b show compound **1** and BRACO-19, respectively, bound to human telomeric quadruplexes. Structures were drawn using the VMD program.⁴⁸

Table 3. Computed Free Energies of Binding for Two Ligand–Quadruplex Complexes

system	computed energy (kcal/mol)			
	complex	quadruplex	ligand	binding
G4-tel + BRACO-19	2949.2	2861.1	74.2	13.9
G4-tel + compound 1	2578.1	2465.4	91.4	21.6

and optimized position of the chromophore is closely similar to that observed in the crystal structure of the naphthalene diimide complex.³⁴ The acridine moiety of the BRACO-19 molecule is asymmetrically stacked on one-half of the terminal G-quartet (Figure 3b). In this arrangement the charged nitrogen atom of the chromophore is situated above the potassium channel at the center of the quadruplex, in accord with the crystal structure.³⁵ The BRACO-19 side chains can only access three grooves, with the anilino group at the 9-position being extremely restricted in its orientation, similarly in accord with the crystal structure. The four side chains in compound **1**, each with a +1 charge, presumably enables it to participate in more electrostatic interactions and thereby contributes to more effective binding than does BRACO-19.

A continuum model for both complexes has been computed that describes electrostatic interactions between each ligand and a quadruplex by numerically solving the Poisson–Boltzmann equation using the program APBS.³⁶ This has enabled relative binding energies of the ligand–quadruplex complexes to be calculated (Table 3) and compared. These energies indicate that BRACO-19 binds with substantially less affinity to a human telomeric quadruplex compared to compound **1**; this ranking is in accord with the order of ΔT_m values (Table 2).

Short-Term Growth Inhibition. Table 4 shows that compound **1** has potent growth inhibitory activity against a range of cancer cell lines, representing human gastric (HGC-27) and colorectal carcinomas (HT-29) as well as the primary KIT-dependent gastrointestinal tumor cell line GIST882. It also shows high activity against the human breast carcinoma cell line MCF-7. The activity of compound **1** is closely comparable with that of imatinib in the GIST882 line, although the former is much more active in the laboratory lines. The established

Table 4. Short-Term Antiproliferative Activity Evaluated by the Sulforhodamine B Assay in Several Cancer Cell Lines, Given as IC_{50} Values in μM , for 96 h of Exposure^a

	GIST882	HGC-27	HT-29	MCF7
imatinib	1.7(2)	2.4(2)	0.06(3)	11.5(3)
compound 1	1.6(2)	0.04(3)	0.03(3)	0.02(3)
BRACO-19	>25.0(3)	2.6(2)	2.7(2)	2.2(2)
TMPyP4	13.2(3)	2.7(2)	4.5(2)	6.1(3)

^a Values are the mean of experiments in triplicate, and esd values are shown in parentheses.

telomeric quadruplex agent BRACO-19^{26–31} on the other hand, while showing activity in the HGC-27, HT-29, and MCF-7 cell lines, has no activity against GIST882 up to at least a 25 μM ligand concentration. The porphyrin molecule TMPyP4 shows a similar profile, although its activity against GIST882 cells is at least 2-fold greater than that of BRACO-19.

The luminescence-based cell viability assay was performed on a larger panel of cell lines for compound **1**, including several non-KIT lines (Figure 4). This confirmed the high level of potency of the compound in the GIST882 cell line, with yet higher potency in the GISTT1 line. In contrast there is little activity in the KIT-negative lines GIST48B and LMS04.

Effects on KIT Transcription and Expression in GIST Cells. This study has focused on the effects of the ligands on the primary GIST cell line GIST882. Figure 5a–c shows that *KIT* mRNA is reduced in a dose-dependent manner following 24 h exposure to compound **1**. At approximately the IC_{50} dose (1 μM) *KIT* mRNA is reduced by ~90% relative to a GAPDH control. No significant changes in *KIT* transcription levels were found with imatinib treatment (Figure 5d,e) or BRACO-19 and TMPyP4 (data not shown). The effects of compound **1** on the transcription of two other proto-oncogenes containing putative quadruplex sequences *MYC*^{16,17,37} and *N-RAS*³⁸ as well as on *hTERT*,³⁹ the catalytic domain of human telomerase, were also examined. A 25–30% change in *MYC* expression was observed, together with a smaller change in *hTERT* and no significant change in *N-RAS* expression (Figures 6).

Immunoblots of KIT protein (Figure 7a,b) show that 24 h of exposure of GIST882 cells to a 1 μM concentration of




Figure 4. Effects of varying concentrations (shown on a logarithmic scale) of compound **1** on the viability of a panel of *KIT*-related cancer cell lines, shown as normalized cell counts.




Figure 5. (a, b) Changes in *KIT* expression in GIST882 cells following 24 h of treatment with compound **1**. Part c shows the quantification of these changes in *KIT* expression normalized against untreated control with GAPDH expression. (d), (e) Changes in *KIT* and GAPDH expression in GIST882 cells following 24 hr treatment with imatinib.

compound **1** results in complete inhibition of *KIT* protein expression. By contrast, *KIT* protein expression levels are unimpaired by imatinib treatment (Figure 7c,d) or by BRACO-19 or TMPyP4 (data not shown).

Effects on Telomerase Activity. Telomerase activity was assessed following exposure of GIST882 cells to compound **1** at a concentration of 0.5 μM (i.e., significantly below the IC_{50} value). Data obtained using the modified TRAP-LIG assay²⁸ show that telomerase activity was absent after this exposure (Figure 8a), indicating potent telomerase inhibition. A subsequent series of long-term cell proliferation studies were performed for 3 weeks of exposure at several subtoxic concentra-

tions. At the lowest, 0.1 μM , some modest effects on proliferation were observed after 2 weeks, when growth started to decrease relative to the control arm of the experiment (Figure 8b). At slightly higher concentrations (0.25, 0.5 μM), growth was more rapidly and profoundly affected, and cell growth and proliferation were completely arrested after week 1 of exposure.

Discussion

We have shown here that the naphthalene diimide derivative **1** has a high level of potency against primary tumor GIST cell lines, whose viability has been established to be *KIT*-dependent.⁶ Moreover, we have shown that this molecule produces 90%




Figure 6. Changes in *MYC* expression in GIST882 cells following 24 h of treatment with compound **1**. Parts a and b represent *MYC* and GAPDH expression, respectively. Part c shows the quantitation of changes in *MYC* expression normalized against untreated control GAPDH expression. Parts d and e show changes in *hTERT* expression in GIST882 cells following 24 h of treatment with compound **1**, showing *hTERT* and GAPDH expression levels, respectively. Part f shows the change in *hTERT* gene expression normalized against untreated control GAPDH expression. The changes in *N-RAS* expression in GIST882 cells following 24 h of treatment with compound **1** are shown in gels (g) *N-RAS* and (h) GAPDH expression, respectively.

down-regulation of *KIT* transcription and complete inhibition of *KIT* protein expression at the same dosage levels as are required for growth inhibition in one of these lines. This is strongly suggestive of the compound acting at the *KIT* gene level; although at this stage it has not been unequivocally demonstrated in cells that compound **1** stabilizes one or both of the two *KIT* promoter quadruplex sequences, it is our current working hypothesis that this is a likely significant contributor to its cellular effects. The hypothesis is also supported by the finding (Figure 4) that compound **1** is significantly less potent in other *KIT*-independent GIST lines. We have also found that compound **1** has selectivity for down-regulating *KIT* expression and does not have a comparable effect on several other cancer-associated genes for which promoter quadruplexes have been postulated, although a more definitive conclusion must await a genome-wide study of the effects of compound **1**. A small effect on *MYC* expression is apparent, which may be related to the amplification of this gene in GIST,³ as well as a small effect on *hTERT* expression, which may be related to the presence of an extended set of G-tracts in the upstream promoter region of this gene.

Surface plasmon resonance studies have previously shown that the naphthalene diimides display exceptionally strong binding to human telomeric quadruplexes,²¹ with K_a values of

$>10^7 \text{ M}^{-1}$. The binding constants of BRACO-19 to a human telomeric quadruplex and a DNA duplex have been estimated, again by surface plasmon resonance, to be 3.1×10^7 and $5 \times 10^5 \text{ M}^{-1}$, respectively.^{30b} By contrast, TMPyP4, as judged by competition dialysis experiments,^{32b} has only modest selectivity for quadruplex over duplex DNA, contrary to data from the melting experiments (Table 2 and Figure 2). Thus, measures of thermal stabilization should only be taken as indicative measures of ligand selectivity and affinity for quadruplex vs duplex DNAs. The molecular modeling studies concur with the trends found in the melting studies for telomeric quadruplexes. We have not undertaken any modeling for the *KIT1* quadruplex drug complexes, since even though a structure is available for this native quadruplex,²⁴ no structural information is available on any ligand complexes. The molecular structure of the *KIT2* quadruplex has not as yet been disclosed.

Compound **1** is the most effective of the three ligands reported here in stabilizing the two *KIT* quadruplexes (Table 2), although the stabilization is relatively slight for the *KIT1* quadruplex compared to the *KIT2* one. The relatively low ability of BRACO-19 to stabilize these quadruplexes appears to be reflected in the low potency of this compound in the GIST882 cell line (Table 4) and inability to affect *KIT* expression and suggests that there is a threshold level of quadruplex stabilization




Figure 7. Immunoblotting of total KIT protein in GIST882 cells. Panel a shows total KIT after treatment with compound **1** for 24 h, and panel b represents an actin control blot. Panel c shows total KIT protein in GIST882 cells treated with imatinib for 24 h, and panel d shows an actin control.

required for a ligand to show these effects. Uptake effects cannot be discounted though, and compound **1** has been shown to be rapidly taken up into cancer cells in culture.²¹ This factor combined with its high quadruplex affinity suggests that there would be sufficient compound **1** available to saturate the very small number of telomeric and *KIT* quadruplex sites even though very many more duplex sites would be available. Future analogues with enhanced quadruplex selectivity are clearly desirable and are the subject of current studies in our laboratories.

Several GIST cell lines have been previously characterized as telomerase-positive (see, for example, ref 40). We have recently shown that compound **1** is an effective inhibitor of telomerase in a small panel of other cancer cell lines.²¹ We report here that the GIST882 line strongly expresses catalytically active telomerase and find that compound **1** produces profound growth arrest after several days of treatment at subtoxic concentrations (Figure 8b), characteristic of quadruplex-mediated inhibition of telomerase.^{27,41,42} This compound is the most potent telomerase inhibitor in the library of naphthalene diimides described previously,²¹ which may explain in part why it is active in patient-derived GIST882 cells. In addition, preliminary studies (Figure 4) have demonstrated similar potency effects in GIST48 cells, which were derived from a patient with GIST progressing on imatinib therapy. GIST48 contains kinase-domain imatinib resistance mutations and is resistant to imatinib in vitro (IC₅₀ of 18.7 μM), whereas the activity of compound **1** remains high (IC₅₀ of 0.5 μM). We suggest that compound **1** and analogues may therefore be useful in the treatment of human GIST (and perhaps other cancers such as leiomyosarcoma and mesothelioma), which is clinically resistant to imatinib or other *KIT*-kinase inhibitor drugs.

The data presented here are consistent with the hypothesis that compound **1** has dual action on both telomerase activity and expression of the *KIT* gene, which plays a key role in the

growth of GIST cell lines, and that the compound is targeting and stabilizing one or both quadruplexes in the *KIT* promoter region, although further studies, beyond the scope of the present paper, will be required to prove that this is the case. This dual action is independent of and unaffected by mutational changes in the *KIT* protein that are consequential to inhibitors acting on the nucleotide-binding domain; we show here that the GIST882 cell line does not contain any mutations in either *KIT* quadruplex sequence, and the same has been found for the GIST48 imatinib-resistant line (data not shown). The availability of cocrystal structures of a naphthalene diimide compound³⁵ with human telomeric quadruplexes may be useful in the rational design of further analogues with improved *KIT* quadruplex specificity, as well as optimized inhibitory and pharmacological properties. These may find use in the therapy of human GIST that is resistant to conventional kinase inhibitors.

Experimental Section

Cell Lines. GIST882 and GISTT1 are human cell lines established from imatinib-sensitive GISTs. GIST882 contains a homozygous K642E *KIT* exon 13 mutation, and GISTT1 has a heterozygous 57-base pair deletion in *KIT* exon 11.^{43,44} GIST48 and GIST430 are human cell lines established from progressing imatinib-resistant GISTs. GIST48 contains a homozygous V560D *KIT* exon 11 primary mutation and a heterozygous D820A *KIT* exon 17 secondary mutation. GIST430 has a heterozygous *KIT* exon 11 in-frame deletion primary mutation and a heterozygous V654A *KIT* exon 13 secondary mutation. GIST48B is a stable subcell line developed from the GIST48 parental cell line. GIST48B was established after 17-AAG drug pressure which resulted in nearly undetectable *KIT* transcript and protein. EWS502 is a human cell line established from a patient with Ewing's sarcoma. EWS502 contains wild-type *KIT* which is overexpressed but not activated. LMS04 and MESO924 are human cell lines established from patients with leiomyosarcoma and mesothelioma, respectively, and contain wild-type *KIT*. GIST882, GISTT1, EWS502, LMS04, and MESO428 were maintained in RPMI 1640 supplemented with 15% fetal bovine serum. GIST430, GIST48, and GIST48B were maintained in F10 supplemented with 15% fetal bovine serum, mito + serum extender, and bovine pituitary extract. HGC-27, HT-29, and MCF-7 cells were purchased from ATCC. MCF-7 and HT-29 cells were both maintained in DMEM. HGC-27 was maintained in MEM. Both DMEM and MEM were supplemented with 10% FBS.

Small Molecule Inhibitors. Imatinib mesylate (Glivec) was purchased from ACC Corporation. A 10 mM stock solution was prepared in 100% DMSO and kept at -20 °C in 10 μL aliquots. Stock solutions of compound **1** as free base were prepared in 100% DMSO and kept at -20 °C. Two established quadruplex-binding ligands, the acridine BRACO-19 (synthesized in-house) and the porphyrin TMPyP4 (purchased from Calbiochem Inc.), were also used in this study. A 1 mM working solution of each compound was freshly prepared in filter-sterilized distilled water with 1% HCl on the day of an experiment.

DNA Melting Studies. FRET DNA melting assays were performed as described previously,²¹ using 96-well plates and an Opticon DNA Engine instrument (MJ Research). Oligonucleotides (Eurogentec Ltd., U.K.) used were the following, where FAM is 6-carboxyfluorescein and TAMRA 6-carboxytetramethylrhodamine: G4-Tel, 5'-FAM-d[G₃(T₂AG₃)₃]-TAMRA-3'; G4-*KIT1*, 5'-FAM-d[AGAG₃AG₂GCGCTG₃AG₂AG₃GCT]-TAMRA-3'; G4-*KIT2*: 5'-FAM-d[C₃G₃CG₃CGCGAG₃AG₄AG₂]-TAMRA-3'; duplex DNA, 5'-FAM-d[(TA)₂GC(TA)₂T₆(TA)₂GC(TA)₂]-TAMRA-3'.

FRET-labeled oligonucleotides were annealed as 400 nM solutions in 60 mM potassium chloride/cacodylate buffer (50 mM potassium chloride + 10 mM potassium hydroxide adjusted to pH 7.4 with cacodylic acid) by heating to 90 °C and allowing to cool slowly to ambient temperature. Into each well of a 96-well plate




Figure 8. (a) Polyacrylamide gel showing telomerase activity in GIST882 cells treated with compound **1** for 1 week: lane 1, vehicle control; lane 2, 0.5 μM compound **1**; lane 3, negative control. (b) Long-term accumulative population doublings of GIST 882 cells treated with increasing concentrations of compound **1**.

was transferred 50 μL of the above solution and, in the case of control wells, 50 μL of buffer added to give a final oligonucleotide concentration of 200 nM. For wells in which the T_m shifts were to be determined, an amount of 25 μL of 2 mM ligand stock in buffer was added together with 25 μL of buffer to give a final ligand concentration of 500 nM. In the case of wells where competition binding was to be measured, the 25 μL of buffer was substituted with 25 μL of calf thymus DNA stock solutions in buffer at base pair concentrations of 2.4, 24, 240, or 480 μM , leading to the final concentrations shown in the caption for Figure 2b. The 96-well plates were measured with a DNA Engine Opticon 1 (MJ Research) with excitation at 450–495 nm and detection at 515–545 nm. Fluorescence readings were taken at intervals of 0.5 $^\circ\text{C}$ over the range 30–100 $^\circ\text{C}$, a ramp rate of 1 $^\circ\text{C min}^{-1}$ being used. Final analysis of the data was carried out using a script written in the program Origin 7.0 (Origin Lab Corp., Northampton, MA). T_m values were determined as the maximum of the derivative of the fluorescence vs temperature plots except for the oligonucleotide *KIT1* where the plots were fitted to a sigmoid curve.


Molecular Modeling Studies. The coordinates from the crystal structures of human telomeric quadruplexes complexed with a naphthalene diimide compound similar to ND1 (PDB code 3CDM) and with BRACO-19 (PDB code 3CE5) were obtained from the Protein Data Bank (PDB). The ligands were built using the Builder module in the Insight II suite of programs (www.accelrys.com). The partial charges for the ligands were derived by fitting the HF/6-31G* electrostatic potential, calculated with the GAMESS ab initio software package.⁴⁵

Docking was performed with the Affinity Docking module of the Insight II package. The ligand binding sites were based on the relative positions of the ligands bound in the crystal structures. This included the terminal G-quartet in the 3CDM structure. The side chains of the closely related naphthalene diimide compound in the 3CDM crystal structure were modified to become compound **1** and were minimized and docked into the structure while keeping the position of the central chromophore fixed. This protocol enables the positioning of the ligand to be close to that observed in the crystal structure.

The next phase of modeling involved simulated annealing. The van der Waals radii were adjusted to their full values, charges included with a distance-dependent dielectric of $4r_{ij}$ and the nonbonded cutoff set to 12 \AA . The system was again minimized for 300 steps of conjugate gradient followed by molecular dynamics simulations. The initial starting temperature was set to 500 K and gradually cooled to 300 K over 10 ps. The resulting structures were

again subjected to 500 steps of conjugate gradient minimization. The final docked model in each case was chosen on the basis of two criteria: total energy of the system and the total number of hydrogen bonds that each ligand made with the quadruplex DNA. The positively charged ions were retained in their crystallographic positions or were assigned between the quartets along the central axis of the structures and were assumed to be integral parts of the systems.

Electrostatics contributions to the overall energy for the implicit models were calculated using the APBS electrostatics package.³⁶ The online PDB2PQR server (http://agave.wustl.edu/pdb2pqr/) was used to prepare the docked complexes for electrostatic calculations by optimizing hydrogen-bonding networks.⁴⁶ Charges, radii, and atom types were assigned to each ligand atom in accordance with the AMBER force field. The systems were then subjected to APBS electrostatic calculations. A dielectric constant of 2, a solvent dielectric of 80, and grid spacing were all optimally chosen such that the grid was always finer than 0.5 \AA . The remaining parameters were kept at default values. The binding free energies were calculated on the basis of the simple thermodynamics cycle,



where [complex, quadruplex, ligand] and [complex_(s), quadruplex_(s), ligand_(s)] represent the nonsolvated and solvated states of the system, respectively. The program APBS calculates binding free energy using the equation

$$\Delta G_{\text{binding}} = -\Delta_3 G = \Delta_4 G - \Delta_1 G - \Delta_2 G \quad (1)$$

This binding free energy cycle illustrates binding in terms of the transfer of free energies from a homogeneous dielectric environment to an inhomogeneous dielectric environment with differing internal and external dielectric constants.³⁶ The contributors to the binding energies are detailed in Table 3.

Gene Expression Using RT-PCR. Changes in the expression of *KIT*, *MYC*, *hTERT*, *N-RAS*, and *GAPDH* genes were measured following exposure to imatinib and compound **1** at subcytotoxic concentrations for 24 h in GIST882 cells. Gene expression changes were monitored using the One-Step Superscript RT-PCR system

Table 5

gene	primer sequences
<i>KIT</i>	forward: TGA CTT ACG ACA GGC TCG TG reverse: AAG GAG TGA ACA GGG TGT GG
<i>MYC</i>	forward: TGG TGC TCC ATG AGG AGA CA reverse: GTG GCA CCT CTT GAG GAC CT
<i>h-TERT</i>	forward: CGG AAG AGT GTC TGG AGC AA reverse: GGA TGA AGC GGA GTC TGG A
<i>N-RAS</i>	forward: CAG GTT CTT GCT GGT GTG AA reverse: CTC TAT GGT GGG ATC ATA TT
<i>GAPDH</i>	forward: GGC AGT GAT GGC ATG GAC TG reverse: CGG GAA GCT TGT GAT CAA TGG

(Invitrogen). The 1×10^6 cells were seeded in T25cm² flasks with appropriate concentrations of drug and incubated as above. At the end of 24 h cells were washed with $1 \times$ PBS, trypsinized, and centrifuged at 8000g for 3 min. Total RNA was extracted from the pellets using the Absolutely RNA Miniprep Kit from Stratagene. Then 250 ng of RNA was used to amplify expression of these genes. PCR products were resolved in 2% agarose gel stained with ethidium bromide. The intensity of each PCR product was quantified using a gel scanner and gene tool software (Sygene, Cambridge, U.K.) and was normalized for each gene against appropriate GAPDH expression. Primers used for the amplification of each gene are given in Table 5.

Western Blotting Analysis of Total KIT Expression. To assess changes in KIT protein expression, protein lysates were prepared from GIST882 cells treated with imatinib at 5 and 10 μ M and compound **1** at 0.5 and 1 μ M for 24 h. Protein concentrations were determined by the Bradford assay followed by electrophoresis and immunoblotting.

Determination of Cellular Telomerase Activity. Inhibition of telomerase activity following long-term exposure to compound **1** was measured using the TRAP-LIG modified telomere repeat amplification protocol assay,²⁸ which is designed to ensure that ligand is not carried over into the second PCR step of the assay. Protein (1000 ng) from GIST882 cells treated for 1 week with compound **1** was incubated with master mix containing the TS forward primer (0.1 μ g of 5'-AAT CCG TCG AGC AGA GTT-3'), TRAP buffer (20 mM Tris-HCl [pH 8.3], 68 mM KCl, 1.5 mM MgCl₂, 1 mM EGTA, 0.05% v/v Tween-20), bovine serum albumin (0.05 μ g), and dNTPs (125 μ M each), protein extract (500 ng/sample) diluted in lysis buffer (10 mM Tris-HCl, pH 7.5, 1 mM MgCl₂, 1 mM EGTA, 0.5% CHAPS, 10% glycerol, 5 mM β -mercaptoethanol, 0.1 mM AEBSEF). Telomerase elongation step was carried out for 10 min at 30 °C, followed by 94 °C for 5 min and a final maintenance of the mixture at 20 °C. Elongated products were purified using QIA quick nucleotide purification kit (Qiagen) according to the manufacturer's instructions. The purified samples were freeze-dried and then redissolved in PCR-grade water at room temperature prior to the amplification step. Purified telomerase extended samples were then subject to PCR amplification. For this, a second PCR master mix was prepared consisting of ACX reverse primer (1 μ M, 5'-GCG CGG [CTTACC]₃ CTA ACC-3'), TS forward primer (0.1 μ g, 5'-AAT CCG TCG AGC AGA GTT-3'), TRAP buffer, BSA (5 μ g), 0.5 mM dNTPs, and 2 U of *TAQ* polymerase (RedHot, ABgene, Surrey, U.K.). An aliquot of 10 μ L of the master mix was added to the purified telomerase extended samples and amplified for 35 cycles of 94 °C for 30 s, at 61 °C for 1 min, and at 72 °C for 1 min. Samples were separated on a 12% PAGE and visualized with SYBR green (Aldrich) staining. Gels were quantified using a gel scanner and gene tool software (Sygene, Cambridge, U.K.). Intensity data were obtained by scanning and integrating the total intensity of each PCR product ladder in the denaturing gels. Drug treated samples were normalized against positive control containing untreated protein only. All samples were corrected for background by subtracting the fluorescence reading of the negative control.

Sequencing the c-Kit Promoter Region. A 943 base pair long *KIT* gene fragment was amplified by two PCR reactions using genomic DNA isolated from GIST882 cells. This comprises 690

nucleotides of the *KIT* promoter region, exon 1, and the initial 100 nucleotides of intron 1. PCR was carried out in a final volume of 50 μ L containing 50 ng of genomic DNA, 50 pmol of each primer (5'-NNNGAATTCACCTCGCCACGCGCC-3' and 5'-NNNNA-AGCTTCGCACTCTCTCCGGATG-3'), 200 μ M of each dNTP, 2.5 U of Herculase polymerase (Stratagene), and $10 \times$ PCR buffer. After being heated for 5 min at 94 °C, the mixture was incubated for 30 cycles with denaturation (90 s, 94 °C), annealing (60 s, 55 °C), and elongation (120 s, 72 °C) steps followed by 10 min extension at 72 °C. The correct-size fragment was separated on agarose gel and ligated into pUC19. DNA sequences of the PCR fragment contained in the vector were determined by Eurofins MWG Operon. Three clones were sequenced from each strand by two independent amplification reactions (PCR_A, PCR_B) and aligned with the sequence taken from the Ensembl Web site (<http://www.ensembl.org>).

In Vitro Assays. Short-term antiproliferative activity in several cancer cell lines was evaluated by the sulforhodamine B assay and calculated as IC₅₀ values in μ M for 96 h exposure.^{21,30} Viability studies were also conducted using the CellTiter-Glo luminescent assay (Promega, Madison, WI) which utilizes a luciferase-catalyzed luciferin/ATP reaction to provide a qualitative measure of metabolically active cells. Cell lines were plated at 10000–30000 cells per well in a 96-well flat bottom plate (Falcon, Lincoln, NJ), cultured in serum-containing media overnight, and treated with compound **1** for 3–6 days, including water-solvent control. The luminescence signal was quantitated using a Veritas microplate luminometer (Turner Biosystems, Sunnyvale, CA) and normalized to the control. All experimental points were measured in triplicate.

Acknowledgment. Grant support was by Cancer Research U.K. Programme Grant and European Union FP6 Molecular Cancer Medicine Grant (to S.N.) and by an anonymous donor, GI SPORE IP50CA127003-02, the Life Raft Group, the Daniel K. Ludwig Trust for Cancer Research, and the Stutman GIST Cancer Research Fund (to J.A.F.).

References

- (1) Yarden, Y.; Kuang, W. J.; Yang-Feng, T.; Coussens, L.; Munemitsu, S.; Dull, T. J.; Chen, E.; Schlessinger, J.; Francke, U.; Ullrich, A. Human proto-oncogene C-Kit. A new cell-surface receptor tyrosine kinase for an unidentified ligand. *EMBO J.* **1987**, *6*, 3341–3351.
- (2) Roskoski, R., Jr. Structure and regulation of Kit protein-tyrosine kinase, the stem cell factor receptor. *Biochem. Biophys. Res. Commun.* **2005**, *37*, 307–1315.
- (3) Yang, J.; Du, X.; Lazar, A. J.; Pollock, R.; Hunt, K.; Chen, K.; Hao, X.; Trent, J.; Zhang, W. Genetic aberrations of gastrointestinal stromal tumors. *Cancer* **2008**, *113*, 1532–1543.
- (4) Fletcher, J. A.; Rubin, B. P. KIT mutations in GIST. *Curr. Opin. Genet. Dev.* **2007**, *7*, 3–7.
- (5) Hoeben, A.; Schoffski, P.; Debiec-Rychter, M. Clinical implications of mutational analysis in gastrointestinal stromal tumours. *Br. J. Cancer* **2008**, *98*, 684–688.
- (6) Tuveson, D. A.; Willis, N. A.; Jacks, T.; Griffin, J. D.; Singer, S.; Fletcher, C. D.; Fletcher, J. A.; Demetri, G. D. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. *Oncogene* **2001**, *20*, 5054–5058.
- (7) Zhu, M. J.; Ou, W. B.; Fletcher, C. D.; Cohen, P. S.; Demetri, G. D.; Fletcher, J. A. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. *Oncogene* **2007**, *26*, 6386–6395.
- (8) Heinrich, M. C.; Corless, C. L.; Demetri, G. D.; Blanke, C. D.; von Mehren, M.; Joensuu, H.; McGreevey, L. S.; Chen, C. J.; Van den Abbeele, A. D.; Druker, B. J.; Kiese, B.; Eisenberg, B.; Roberts, P. J.; Singer, S.; Fletcher, C. D.; Silberman, S.; Dimitrijevic, S.; Fletcher, J. A. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J. Clin. Oncol.* **2003**, *21*, 4342–4349.
- (9) Heinrich, M. C.; Corless, C. L.; Blanke, C. D.; Demetri, G. D.; Joensuu, H.; Roberts, P. J.; Eisenberg, B. L.; von Mehren, M.; Fletcher, C. D.; Sandau, K.; McDougall, K.; Ou, W. B.; Chen, C. J.; Fletcher, J. A. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J. Clin. Oncol.* **2006**, *24*, 4764–4774.
- (10) von Mehren, M. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. *Clin. Colorectal Cancer* **2006**, *6*, S30–S34.
- (11) Abrams, T. J.; Lee, L. B.; Murray, L. J.; Pryer, N. K.; Cherringham, J. M. SU11248 inhibits KIT and platelet-derived growth factor receptor

- beta in preclinical models of human small cell lung cancer. *Mol. Cancer Ther.* **2003**, *2*, 471–478.
- (12) Le Tourneau, C.; Raymond, E.; Faivre, S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). *Ther. Clin. Risk Manage.* **2007**, *3*, 341–348.
- (13) Liegl, B.; Kepten, L.; Le, C.; Zhu, M.; Demetri, G. D.; Heinrich, M. C.; Fletcher, C. D.; Corless, C. L.; Fletcher, J. A. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. *J. Pathol.* **2008**, *216*, 64–74.
- (14) Monchaud, D.; Teulade-Fichou, M. P. A hitchhiker's guide to G-quadruplex ligands. *Org. Biomol. Chem.* **2008**, *6*, 627–636.
- (15) Tan, J. H.; Gu, L. Q.; Wu, J. Y. Design of selective G-quadruplex ligands as potential anticancer agents. *Mini-Rev. Med. Chem.* **2008**, *8*, 1163–1178.
- (16) Siddiqui-Jain, A.; Grand, C. L.; Bearss, D. J.; Hurley, L. H. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 11593–11598.
- (17) Hurley, L. H.; Von Hoff, D. D.; Siddiqui-Jain, A.; Yang, D. Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. *Semin. Oncol.* **2006**, *33*, 498–512.
- (18) Liu, J. N.; Deng, R.; Guo, J. F.; Zhou, J. M.; Feng, G. K.; Huang, Z. S.; Gu, L. Q.; Zeng, Y. X.; Zhu, X. F. Inhibition of myc promoter and telomerase activity and induction of delayed apoptosis by SYUIQ-5, a novel G-quadruplex interactive agent in leukemia cells. *Leukemia* **2007**, *21*, 1300–1302.
- (19) Bejugam, M.; Sewitz, S.; Shirude, P. S.; Rodriguez, R.; Shahid, R.; Balasubramanian, S. Trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands: small molecule regulation of c-kit oncogene expression. *J. Am. Chem. Soc.* **2007**, *129*, 12926–12927.
- (20) Yamamoto, K.; Tojo, A.; Aoki, N.; Shibuya, M. Characterization of the promoter region of the human c-kit proto-oncogene. *Jpn. J. Cancer Res.* **1993**, *84*, 1136–1144.
- (21) Cuenca, F.; Greciano, O.; Gunaratnam, M.; Haider, S.; Munnar, D.; Nanjunda, R.; Wilson, W. D.; Neidle, S. Tri- and tetra-substituted naphthalene diimides as potent G-quadruplex ligands. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 1668–1673.
- (22) Rankin, S.; Reszka, A. P.; Huppert, J.; Zloh, M.; Parkinson, G. N.; Todd, A. K.; Ladame, S.; Balasubramanian, S.; Neidle, S. Putative DNA quadruplex formation within the human c-kit oncogene. *J. Am. Chem. Soc.* **2005**, *127*, 10584–10589.
- (23) Fernando, H.; Reszka, A. P.; Huppert, J.; Ladame, S.; Rankin, S.; Venkitaraman, A. R.; Neidle, S.; Balasubramanian, S. A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene. *Biochemistry* **2006**, *45*, 7854–7860.
- (24) Phan, A. T.; Kuryavyi, V.; Burge, S.; Neidle, S.; Patel, D. J. Structure of an unprecedented G-quadruplex scaffold in the human c-kit promoter. *J. Am. Chem. Soc.* **2007**, *129*, 4386–4392.
- (25) Todd, A. K.; Haider, S. M.; Parkinson, G. N.; Neidle, S. Sequence occurrence and structural uniqueness of a G-quadruplex in the human c-kit promoter. *Nucleic Acids Res.* **2007**, *35*, 5799–5808.
- (26) Schultes, C. M.; Guyen, B.; Cuesta, J.; Neidle, S. Synthesis, biophysical and biological evaluation of 3,6-bis-amidoacridines with extended 9-anilino substituents as potent G-quadruplex-binding telomerase inhibitors. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 4347–4351.
- (27) Gunaratnam, M.; Greciano, O.; Martins, C.; Reszka, A. P.; Schultes, C. M.; Morjani, H.; Riou, J. F.; Neidle, S. Mechanism of acridine-based telomerase inhibition and telomere shortening. *Biochem. Pharmacol.* **2007**, *74*, 679–689.
- (28) Reed, J. E.; Gunaratnam, M.; Beltran, M.; Reszka, A. P.; Vilar, R.; Neidle, S. TRAP-LIG, a modified TRAP assay to quantitate telomerase inhibition by small molecules. *Anal. Biochem.* **2008**, *380*, 99–105.
- (29) Read, M.; Harrison, R. J.; Romagnoli, B.; Tanious, F. A.; Gowan, S. M.; Reszka, A. P.; Wilson, W. D.; Kelland, L. R.; Neidle, S. Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 4844–4849.
- (30) (a) Harrison, R. J.; Cuesta, J.; Chessari, G.; Read, M. A.; Basra, S. K.; Reszka, A. P.; Morrell, J.; Gowan, S. M.; Incles, C. M.; Tanious, F. A.; Wilson, W. D.; Kelland, L. R.; Neidle, S. Trisubstituted acridine derivatives as potent and selective telomerase inhibitors. *J. Med. Chem.* **2003**, *46*, 4463–4476. (b) White, E. W.; Tanious, F.; Ismail, M. A.; Reszka, A. P.; Neidle, S.; Boykin, D. W.; Wilson, W. D. Structure-specific recognition of quadruplex DNA by organic cations: influence of shape, substituents and charge. *Biophys. Chem.* **2007**, *126*, 140–153.
- (31) Burger, A. M.; Dai, F.; Schultes, C. M.; Reszka, A. P.; Moore, M. J.; Double, J. A.; Neidle, S. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. *Cancer Res.* **2005**, *65*, 1489–1496.
- (32) (a) Wheelhouse, R. T.; Sun, D. K.; Han, H. Y.; Han, F. X. G.; Hurley, L. H. Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(*N*-methyl-4-pyridyl)porphyrine with quadruplex DNA. *J. Am. Chem. Soc.* **1998**, *120*, 3261–3262. (b) Ren, J.; Chaires, J. B. Sequence and structural selectivity of nucleic acid binding ligands. *Biochemistry* **1999**, *38*, 16067–16075.
- (33) (a) Parkinson, G. N.; Lee, M. P.; Neidle, S. Crystal structure of parallel quadruplexes from human telomeric DNA. *Nature* **2002**, *417*, 876–880. (b) Phan, A. T.; Kuryavyi, V.; Luu, K. N.; Patel, D. J. Structure of two intramolecular G-quadruplexes formed by natural human telomere sequences in K⁺ solution. *Nucleic Acids Res.* **2007**, *35*, 6517–6525. (c) Ambrus, A.; Chen, D.; Dai, J.; Bialis, T.; Jones, R. A.; Yang, D. Human telomeric sequence forms a hybrid-type intramolecular G-quadruplex structure with mixed parallel/antiparallel strands in potassium solution. *Nucleic Acids Res.* **2006**, *34*, 2723–2735. (d) Dai, J.; Carver, M.; PUNCHIHEWA, C.; Jones, R. A.; Yang, D. Structure of the hybrid-2 type intramolecular human telomeric G-quadruplex in K⁺ solution: insights into structure polymorphism of the human telomeric sequence. *Nucleic Acids Res.* **2007**, *35*, 4927–4740. (e) Lim, K. W.; Amrane, S.; Bouaziz, S.; Xu, W.; Mu, Y.; Patel, D. J.; Luu, K. N.; Phan, A. T. Structure of the human telomere in K(+) solution: a stable basket-type G-quadruplex with only two G-tetrad layers. *J. Am. Chem. Soc.* **2009**, *131*, 4301–4309.
- (34) Parkinson, G. N.; Cuenca, F.; Neidle, S. Topology conservation and loop flexibility in quadruplex–drug recognition: crystal structures of inter- and intramolecular telomeric DNA quadruplex–drug complexes. *J. Mol. Biol.* **2008**, *381*, 1145–1156.
- (35) Campbell, N. H.; Parkinson, G. N.; Reszka, A. P.; Neidle, S. Structural basis of DNA quadruplex recognition by an acridine drug. *J. Am. Chem. Soc.* **2008**, *130*, 6722–6724.
- (36) Baker, N. A.; Sept, D.; Joseph, S.; Holst, M. J.; McCammon, J. A. Electrostatics of nanosystems: application to microtubules and the ribosome. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 10037–10041 (program available at <http://apbs.sf.net>).
- (37) Simonsson, T.; Pecinka, P.; Kubista, M. DNA tetraplex formation in the control region of c-myc. *Nucleic Acids Res.* **1998**, *26*, 1167–1172.
- (38) Kumari, S.; Bugaut, A.; Huppert, J. L.; Balasubramanian, S. An RNA G-quadruplex in the 5' UTR of the NRAS proto-oncogene modulates translation. *Nat. Chem. Biol.* **2007**, *3*, 218–221.
- (39) Gomez, D.; Lemarteleur, T.; Lacroix, L.; Mailliet, P.; Mergny, J.-L.; Riou, J.-F. Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing. *Nucleic Acids Res.* **2004**, *32*, 371–379.
- (40) Sakurai, S.; Fukayama, M.; Kaizaki, Y.; Saito, K.; Kanazawa, K.; Kitamura, M.; Iwasaki, Y.; Hishima, T.; Hayashi, Y.; Koike, M. Telomerase activity in gastrointestinal stromal tumors. *Cancer* **1998**, *83*, 2060–2066.
- (41) Hahn, W. C.; Stewart, S. A.; Brooks, M. W.; York, S. G.; Eaton, E.; Kurachi, A.; Beijersbergen, R. L.; Knoll, J. H.; Meyerson, M.; Weinberg, R. A. Inhibition of telomerase limits the growth of human cancer cells. *Nat. Med.* **1999**, *5*, 1164–1170.
- (42) Mergny, J. L.; Lacroix, L.; Teulade-Fichou, M. P.; Hounsou, C.; Guittat, L.; Hoarau, M.; Arimondo, P. B.; Vigneron, J. P.; Lehn, J. M.; Riou, J. F.; Garestier, T.; Helene, C. Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 3062–3067.
- (43) Lux, M. L.; Rubin, B. P.; Biase, T. L.; Chen, C. J.; Maclure, T.; Demetri, G.; Xiao, S.; Singer, S.; Fletcher, C. D.; Fletcher, J. A. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. *Am. J. Pathol.* **2000**, *156*, 791–795.
- (44) Taguchi, T.; Sonobe, H.; Toyonaga, S.; Yamasaki, I.; Shuin, T.; Takano, A.; Araki, K.; Akimaru, K.; Yuri, K. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. *Lab. Invest.* **2002**, *82*, 663–665.
- (45) Guest, M. F.; Bush, I. J.; van Dam, H. J. J.; Sherwood, P.; Thomas, J. M. H.; van Lenthe, J. H.; Havenith, R. W. A.; Kendrick, J. The GAMESS-UK electronic structure package: algorithms, developments and applications. *Mol. Phys.* **2005**, *103*, 719–747.
- (46) Dolinsky, T. J.; Nielsen, J. E.; McCammon, J. A.; Baker, N. A. PDB2PQR: an automated pipeline for the setup, execution, and analysis of Poisson–Boltzmann electrostatics calculations. *Nucleic Acids Res.* **2004**, *32*, W665–W667.
- (47) Connolly, M. L. Analytical molecular surface calculation. *J. Appl. Crystallogr.* **1983**, *16*, 548–558.
- (48) Humphrey, W.; Dalke, A.; Schulten, K. VMD—Visual Molecular Dynamics. *J. Mol. Graphics* **1996**, *14*, 33–38.